« Return to News | Clinical Intelligence

Bayer reports interim results of safety study on oral contraceptives

Tuesday, March 29, 2011 12:59 PM

Bayer HealthCare Pharmaceuticals announced interim results from a large, prospective, observational cohort safety study that offer insights into the increased risk of venous thromboembolism (VTE), or blood clots, which is a well-established risk in women who use combination oral contraceptives (COCs), also known as “the pill.”

Specifically, the new data provides healthcare providers with information regarding when the VTE risk associated with COCs is highest.  The risk of VTE is highest during the first year of COC use and the new data suggest that this increased risk is greatest during the first six months.  This risk is greatest when first starting “the pill” and when restarting the same or a different “pill” after a four-week or greater break.

The new data are from the ongoing, Long-Term Active Surveillance Study for Oral Contraceptives (LASS)—a large, multinational, prospective-cohort, five-year follow-up safety study to the European Active Surveillance (EURAS) study.  Cardiovascular events, including VTE, were the main clinical outcomes studied in LASS. Together, these two studies will provide data for up to 10 years on women using various COCs.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.